AmeliMojarad Mandana, AmeliMojarad Melika, Cui Xiaonan
Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, PR China.
Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, PR China.
Pathol Res Pract. 2023 Apr;244:154338. doi: 10.1016/j.prp.2023.154338. Epub 2023 Jan 23.
One of the mechanisms by which tumor cells can evade the immune system is over activation of the programmed cell death protein-1 (PD-1) / programmed death-ligand 1 (PD-L1) pathway. The binding of PD-1 to its ligand PD-L1 can trigger an inhibitory signal for reducing T-cell proliferation, inhibiting the anticancer effect of T cells, and limiting the anti-tumor immunity of effectors T cell responses to protect tissues from immune-mediated tissue damage in the tumor microenvironment (TME). PD-1/PD-L1 immune checkpoint inhibitors have created a new pattern in cancer immunotherapy and can increase T cell- surveillance; therefore, the development of better clinical application of PD-1/PD-L1 inhibitors can significantly enhance antitumor immunity and prolong survival in GI cancer patients.
肿瘤细胞逃避免疫系统的机制之一是程序性细胞死亡蛋白-1（PD-1）/程序性死亡配体-1（PD-L1）通路的过度激活。PD-1与其配体PD-L1的结合可触发抑制性信号，以减少T细胞增殖、抑制T细胞的抗癌作用，并限制效应T细胞反应的抗肿瘤免疫力，从而保护肿瘤微环境（TME）中的组织免受免疫介导的组织损伤。PD-1/PD-L1免疫检查点抑制剂开创了癌症免疫治疗的新模式，可增强T细胞监测；因此，更好地临床应用PD-1/PD-L1抑制剂可显著增强胃肠道癌症患者的抗肿瘤免疫力并延长生存期。
